Desktop Genetics Ltd, a UK bioinformatics company aiming to revolutionize the way genetic researchers work, has recently announced that it has secured an investment of £1.37M GBP from a syndicate of ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results